{'fraction_non_alphanumeric': 0.03901532745006967, 'fraction_numerical': 0.03808639108221087, 'mean_word_length': 5.033613445378151, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Fulguration of Ventricular Tachycardia Using High Cumulative Energy: Results in Thirty‐one Patients with a Mean Follow‐Up of Twenty‐seven Months

Catheter electrical ablation of ventricular tachycardia (VT) was attempted in 31 patients (57 ± 15 years) who had refractory recurrent VT. Fifteen patients had coronary artery disease, seven had arrhythmogenic right ventricular dysplasia, four had cardiomyopathy and five had no structural heart disease. Ten patients were NYHA class III‐IV. Ten patients experienced cardiac arrest or syncope during VT. Twenty‐two patients had only one documented morphologic type of spontaneous VT. Whereas nine patients had more than one: the VT was incessant or daily in 17 patients. One to 16 shocks (mean 5.6) of 160 to 240 joules each (1162 ± 1060 joules) were delivered to the endocardial exit site of VT—as identified by endocardial activation mapping (29 patients) and pacemapping (31 patients)—during one (22 patients) or more than one session (nine patients). Cumulative delivered energy was 840 ± 558 joules for right ventricular VT (11 patients) and 1362 ± 1240 joules for left ventricular VT (20 patients). Reversible side effects occurring immediately after shocks included: nonclinical VT (two patients), ventricular fibrillation (two patients), AV block (three patients). Mean CK—MB fraction 6 hours after shocks was 93 ± 46 IU/1. An electrophysiology study performed 7 to 10 days later demonstrated that the original clinical VT was inducible in seven patients, nonclinical monomorphic VT was inducible in eight patients and no VT was inducible in 13 patients. The procedure was successful in 25/29 patients (86%) who had no recurrence of the original VT (or sudden death) either on no antiarrhythmic therapy (16 patients) or on the same regimen that was ineffective before ablation (nine patients) over a follow‐up period of 27 ± 11 months. A nonclinical VT occurred in two patients. The ablation result was not interpretable in two patients and unsuccessful in four patients: the endocardial activation time at site of shocks was –5 ± 5 ms in the failures versus −43 ± 29 ms in the successes (P < 0.05).